Beyond statins: What to expect from add-on lipid regulating therapy?

European Heart Journal

Volumn 34, Issue 34, 2013, Pages 2660-2665

  Laufs, Ulrich ^a   Weintraub, William S ^b   Packard, Chris J ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANACETRAPIB; APOLIPOPROTEIN B; ATORVASTATIN; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ADD ON THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MYALGIA; NONHUMAN; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; VASCULARIZATION; VASODILATATION;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84885463496     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht213     Document Type: Review

References (21)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, SourjinaT, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists C. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
2. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681
3. Ford I, Murray H, Packard CJ, Shepherd J, MacfarlanePW, Cobbe SM, West of Scotland Coronary Prevention Study G. Long-Term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486
4. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000;86:257-262
5. Heart Protection Study Collaborative G, Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: A randomised controlled trial. Lancet 2011;378:2013-2020
6. Perk J, DeBacker G, Gohlke H, GrahamI, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular P, Rehabilitation, Guidelines ESCCfP. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701
7. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES. Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-940
8. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-1900
9. Ference BA, YooW, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, WilliamsKASr, Flack JM. Effect of long-Termexposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J Am Coll Cardiol 2012;60:2631-2639
10. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-329
11. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89-118
12. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterollowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-691
13. Laufs U, Custodis F, BöhmM.Whodoes not need a statin: Too late in end-stage renal disease or heart failure? Heart 2008;94:1138-1140
14. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal OI. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099
15. Catapano AL, Reiner Z, DeBacker G, GrahamI, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, StoreyRF, Wood D, European Society of C, European Atherosclerosis S. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217: 3-46
16. Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-Analysis for low-density lipoprotein lowering. J Clin Lipidol 2012;6:303-309
17. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes.NEngl J Med 2010;363:692-694; author reply 694-5
18. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: The Treating to New Targets (TNT) study. Circulation 2012;125:1979-1987
19. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-Analysis. JAMA 2012;307:1302-1309
20. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J 2011;32:264-268
21. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: A population-based cohort study. Arch Intern Med 2009;169:260-268